Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001567619-23-004269 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-02 | 2023-02-28+ | ARQT | Lock Kenneth A. | Chief Commercial Off | S - Sale | $15.96 | -2,368 | 43.3K | -5% | -$37.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | S | D | 18 | $16.52 | 43,260 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-28 | S | D | 936 | $16.17 | 44,692 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 1,617 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2022. |
| 3 | Common | Common Stock | 2023-03-02 | S | D | 1,414 | $15.82 | 43,278 | D | — | — | (F4) The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |